Adrian J Folkes

Summary

Affiliation: The Royal Veterinary College

Publications

  1. ncbi The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer
    Adrian J Folkes
    Piramed Pharma, 957 Buckingham Avenue, Slough, Berks SL1 4NL, United Kingdom
    J Med Chem 51:5522-32. 2008
  2. ncbi Novel angular benzophenazines: dual topoisomerase I and topoisomerase II inhibitors as potential anticancer agents
    Nigel Vicker
    Medicinal Chemistry Department, Xenova Ltd, 957 Buckingham Avenue, Slough, Berkshire, SL1 4NL, UK
    J Med Chem 45:721-39. 2002

Collaborators

Detail Information

Publications2

  1. ncbi The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer
    Adrian J Folkes
    Piramed Pharma, 957 Buckingham Avenue, Slough, Berks SL1 4NL, United Kingdom
    J Med Chem 51:5522-32. 2008
    ..This work resulted in the discovery of 17, GDC-0941, which is a potent, selective, orally bioavailable inhibitor of PI3K and is currently being evaluated in human clinical trials for the treatment of cancer...
  2. ncbi Novel angular benzophenazines: dual topoisomerase I and topoisomerase II inhibitors as potential anticancer agents
    Nigel Vicker
    Medicinal Chemistry Department, Xenova Ltd, 957 Buckingham Avenue, Slough, Berkshire, SL1 4NL, UK
    J Med Chem 45:721-39. 2002
    ....